L-Glutamine

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: digestion muscle immunity

Research Overview

Across the provided abstracts, L-glutamine (Gln) research is most developed in three areas: (1) disease-modifying therapy for sickle cell disease (SCD) in humans, where it is positioned as an adjunct or second-line option alongside hydroxyurea and newer agents; (2) fundamental and translational metabolism, emphasizing the glutamine–α-ketoglutarate (AKG) axis and its roles in energy production (TCA cycle), biosynthesis (nucleotides, proteins, lipids), and redox balance (glutathione); and (3) nutrition and physiology in animals—particularly ruminants—where Gln/Glu are framed as “functional amino acids” supporting intestinal metabolism, growth, and productivity. A fourth, emerging theme is cardiovascular biology, where Gln is described as influencing vascular cell behavior and systemic cardiometabolic risk factors through antioxidant, anti-inflammatory, and nitric oxide–related mechanisms.

The strongest evidence in these abstracts supports clinical benefit in SCD: randomized trial data summarized in the reviews indicate L-glutamine reduces hospitalization rates (reported ~33% reduction) and shortens mean length of stay compared with placebo, supporting its regulatory approval and clinical use as an adjunctive therapy. Outside SCD, the evidence base presented is largely mechanistic and preclinical/physiologic: Gln is consistently implicated as a key metabolic substrate and signaling-modulating nutrient that can bolster antioxidant defenses (e.g., via glutathione and stress-response proteins) and serve as a precursor supporting nitric oxide synthesis through arginine-related pathways. In ruminants, controlled nutrition studies summarized suggest supplementation at specified doses can improve digestive, endocrine, and reproductive functions, although these findings are context-specific to animal production systems and do not directly establish human clinical efficacy.

Key gaps highlighted or implied include the need for more longitudinal and implementation-focused studies in SCD to optimize real-world outcomes and define best use alongside other disease-modifying agents. In cardiovascular and broader metabolic disease contexts, the abstracts emphasize promise but also potential risk: excessive glutaminolysis may contribute to maladaptive angiogenesis and pulmonary arterial hypertension, indicating a need to clarify dose–response relationships, patient selection, and biomarkers of benefit versus harm. Finally, while the glutamine–AKG axis is proposed as a therapeutic target (including in cancer-related metabolism), the abstracts primarily describe pathway biology; more rigorous translational and clinical trials are needed to determine when supplementation versus inhibition of glutamine utilization is appropriate, and to establish efficacy and safety across specific diseases and populations.

1. What conditions has L-Glutamine been studied for?

  • Sickle cell disease (SCD) (disease-modifying/adjunctive therapy; prevention of acute complications).

  • Cardiometabolic and cardiovascular conditions (reviewed as relevant to hypertension, hyperlipidemia, glucose intolerance/diabetes, obesity; ischemia-reperfusion injury; heart failure; and pulmonary arterial hypertension via glutaminolysis-related mechanisms).

  • Cancer metabolism (as a target/pathway) (the “glutamine–alpha-ketoglutarate axis” discussed as a therapeutic target; not the same as evidence that oral supplementation treats cancer).

  • Diabetic retinopathy (DR) (as a metabolomic biomarker repeatedly identified across studies, not as a proven treatment).

  • Animal production/intestinal health in ruminants (digestive/endocrine/reproductive function and productivity; veterinary/agricultural context).

2. Does it work in treating those conditions? Summarize the evidence.

  • Sickle cell disease (best direct clinical evidence in these abstracts): Two SCD-focused reviews state that L-glutamine is FDA-approved (since 2017) as an adjunctive/second-line disease-modifying therapy. One abstract reports that in clinical trials, L-glutamine:

    • Reduced hospitalization rates by 33% vs placebo.

    • Reduced mean length of stay from 11 to 7 days vs placebo.

    Another SCD review emphasizes that oxidative stress is important in SCD and that L-glutamine has antioxidant-related roles, but also notes that its impact on redox biology in SCD is “not fully understood” and that more research is needed to clarify clinical effects and role in therapy.

  • Cardiovascular/cardiometabolic disease: The cardiovascular review describes “many studies” suggesting glutamine supplementation is protective across cardiometabolic disease and certain injuries (e.g., ischemia-reperfusion) and “may be beneficial” in heart failure, but the abstract does not provide specific trial sizes, effect sizes, or outcomes. It also highlights a potential risk pathway (see Downsides) related to pulmonary arterial hypertension under certain metabolic conditions (excessive glutaminolysis).

  • Diabetic retinopathy: The DR review identifies L-glutamine as a repeatedly altered metabolite across human metabolomics studies and suggests it could be a biomarker for risk stratification. This is not evidence that supplementation treats or prevents DR.

  • Cancer: The glutamine–AKG axis review frames glutamine metabolism as a potential therapeutic target to “counteract cancer,” but this is mechanistic/pathway-focused and does not establish that glutamine supplementation is an effective cancer treatment.

  • Ruminant health/productivity: The ruminant nutrition review states that supplementation with appropriate doses (example given: ~1 g/kg body weight/day for glutamine) can “safely improve” digestive, endocrine, and reproductive functions to enhance productivity. This evidence is in animals and does not directly translate to human clinical outcomes.

3. What health benefits does it have?

  • In SCD (clinical benefit): Reduced hospitalizations and shorter hospital stays versus placebo in clinical trials, as summarized in an SCD review abstract.

  • Antioxidant/redox support (mechanistic rationale): An SCD-focused review notes glutamine’s roles in synthesis of antioxidants and redox cofactors, including:

    • Reduced glutathione

    • NAD(H) and NADP(H)

    • Nitric oxide (NO) (via related pathways)

  • Vascular/cardiometabolic support (review-level claims): The cardiovascular review describes anti-inflammatory and antioxidant effects (e.g., induction of heme oxygenase-1, heat shock proteins, glutathione) and suggests glutamine may mitigate risk factors such as hypertension, hyperlipidemia, glucose intolerance, obesity, and diabetes; it also notes potential benefit in ischemia-reperfusion injury and possibly heart failure (without providing specific clinical effect sizes in the abstract).

  • Metabolic roles (general physiology): The glutamine metabolism review describes glutamine as “semi-essential” and central to cellular energy and biosynthesis via conversion to alpha-ketoglutarate and entry into the TCA cycle, supporting cell growth and homeostasis.

  • Gut/intestinal fuel and amino acid precursor roles (animal-focused but biologically relevant): The ruminant review emphasizes glutamine/glutamate as major metabolic fuels and substrates for synthesis of glutathione and multiple amino acids (e.g., arginine, citrulline, proline), with downstream relevance to nitric oxide (vasodilation) and collagen production.

4. Does it have any downsides or side effects?

  • Uncertainty/gaps in understanding (SCD): The SCD oxidative stress review explicitly states that glutamine’s relative impact on the redox environment in SCD red blood cells is not fully understood and that there are few therapeutic trials—so there is residual uncertainty about mechanisms and optimal use despite FDA approval.

  • Potential harm in specific cardiovascular contexts (mechanistic/preclinical concern): The cardiovascular review warns that excessive shunting of glutamine into the Krebs cycle can drive aberrant angiogenic responses and contribute to pulmonary arterial hypertension. This suggests that in some disease states, increasing glutamine availability could theoretically be counterproductive, and that inhibiting glutaminolysis enzymes has shown promise in preclinical models.

  • Side effects not detailed in these abstracts: None of the provided abstracts list common adverse events (e.g., GI symptoms) or contraindications for human supplementation. Therefore, a side-effect profile cannot be responsibly summarized from these abstracts alone.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

  • Beneficial in a specific genetic disease context (SCD): Sickle cell disease is caused by mutations in the β-globin gene leading to sickle hemoglobin. The SCD abstracts describe L-glutamine as an FDA-approved adjunctive/second-line therapy and report reduced hospitalizations and length of stay versus placebo in trials. This supports benefit in the context of this inherited hemoglobin disorder.

  • No pharmacogenomic stratification described: The abstracts do not report differential response or toxicity by genotype (e.g., specific SCD genotypes, or variants in glutamine metabolism/transport genes). They also do not identify genetic subgroups in diabetes/cardiovascular disease where glutamine is clearly beneficial or harmful.

  • Mechanism-based caution rather than genotype-based guidance: The cardiovascular review’s concern about pulmonary arterial hypertension relates to metabolic routing (glutaminolysis) rather than a specific genetic variant; no actionable pharmacogenomic recommendations can be made from these abstracts.

References

  1. Sickle Cell Disease: A Review.
    Patricia L Kavanagh, Titilope A Fasipe, Ted Wun (2022) - JAMA
  2. Advances in the diagnosis and treatment of sickle cell disease.
    A M Brandow, R I Liem (2022) - Journal of hematology & oncology
  3. Metabolism and Nutrition of L-Glutamate and L-Glutamine in Ruminants.
    Guoyao Wu, Fuller W Bazer, Gregory A Johnson, M Carey Satterfield, Shannon E Washburn (2024) - Animals : an open access journal from MDPI
  4. The Emerging Role of l-Glutamine in Cardiovascular Health and Disease.
    William Durante (2019) - Nutrients
  5. The glutamine-alpha-ketoglutarate (AKG) metabolism and its nutritional implications.
    Dingfu Xiao, Liming Zeng, Kang Yao, Xiangfeng Kong, Guoyao Wu, Yulong Yin (2016) - Amino acids
  6. An overview of biological production of L-theanine.
    Wanmeng Mu, Tao Zhang, Bo Jiang (2015) - Biotechnology advances
  7. What makes a good new therapeutic L-asparaginase?
    Angela Beckett, David Gervais (2019) - World journal of microbiology & biotechnology
  8. Metabolomics in Diabetic Retinopathy: A Systematic Review.
    Xiao-Wen Hou, Ying Wang, Chen-Wei Pan (2021) - Investigative ophthalmology & visual science
  9. L-glutamine for sickle cell disease: Knight or pawn?
    Alina Sadaf, Charles T Quinn (2020) - Experimental biology and medicine (Maywood, N.J.)
  10. l-glutamine, crizanlizumab, voxelotor, and cell-based therapy for adult sickle cell disease: Hype or hope?
    Jennifer N Leibovitch, Ajay V Tambe, Emanuela Cimpeanu, Maria Poplawska, Firas Jafri, Dibyendu Dutta, Seah H Lim (2022) - Blood reviews
  11. L-glutamine sensitizes Gram-positive-resistant bacteria to gentamicin killing.
    Lvyuan Fan, Zhiyu Pan, Yilin Zhong, Juan Guo, Xu Liao, Rui Pang, Qingqiang Xu, Guozhu Ye, Yubin Su (2023) - Microbiology spectrum
  12. Effect of oral l-Glutamine supplementation on Covid-19 treatment.
    Mahir Cengiz, Betul Borku Uysal, Hande Ikitimur, Erkan Ozcan, Mehmet Sami Islamoğlu, Emre Aktepe, Hakan Yavuzer, Serap Yavuzer (2020) - Clinical nutrition experimental
  13. Effect of Supplementing Different Levels of L-Glutamine on Holstein Calves during Weaning.
    Shuo Wang, Fuwei Wang, Fanlin Kong, Zhijun Cao, Wei Wang, Hongjian Yang, Yajing Wang, Yanliang Bi, Shengli Li (2022) - Antioxidants (Basel, Switzerland)
  14. L-Glutamine alleviates osteoarthritis by regulating lncRNA-NKILA expression through the TGF-β1/SMAD2/3 signalling pathway.
    Xiao Ma, Dechao Cai, Yakun Zhu, Yao Zhao, Xianbo Shang, Chen Wang, Haotian Zhang, Ashuai Bian, Haoran Yu, Wendan Cheng (2022) - Clinical science (London, England : 1979)
  15. L-glutamine protects mouse brain from ischemic injury via up-regulating heat shock protein 70.
    Long-Long Luo, Yong-Fang Li, Hui-Min Shan, Li-Ping Wang, Fang Yuan, Yuan-Yuan Ma, Wan-Lu Li, Ting-Ting He, Yu-Yang Wang, Mei-Jie Qu, Huai-Bin Liang, Zhi-Jun Zhang, Guo-Yuan Yang, Yao-Hui Tang, Yong-Ting Wang (2019) - CNS neuroscience & therapeutics
  16. Marine microbial L-glutaminase: from pharmaceutical to food industry.
    Noora Barzkar, Muhammad Sohail, Saeid Tamadoni Jahromi, Reza Nahavandi, Mojgan Khodadadi (2021) - Applied microbiology and biotechnology
  17. Oral L-glutamine administration attenuated cutaneous wound healing in Wistar rats.
    Saurabh Goswami, Amit Kandhare, Anand A Zanwar, Mahabaleshwar V Hegde, Subhash L Bodhankar, Sudhir Shinde, Shahaji Deshmukh, Ravindran Kharat (2016) - International wound journal
  18. L-Glutamine deprivation induces autophagy and alters the mTOR and MAPK signaling pathways in porcine intestinal epithelial cells.
    Yuhua Zhu, Gang Lin, Zhaolai Dai, Tianjiao Zhou, Tiantian Li, Taolin Yuan, Zhenlong Wu, Guoyao Wu, Junjun Wang (2015) - Amino acids
  19. L-glutamine for sickle cell disease: more than reducing redox.
    Firas Jafri, Gyuhee Seong, Tim Jang, Emanuela Cimpeanu, Maria Poplawska, Dibyendu Dutta, Seah H Lim (2022) - Annals of hematology
  20. Supplementation of L-glutamine enhanced mucosal immunity and improved hormonal status of combat-sport athletes.
    Tung-Lin Lu, Ai-Chi Zheng, Katsuhiko Suzuki, Chi-Cheng Lu, Chung-Yuan Wang, Shih-Hua Fang (2024) - Journal of the International Society of Sports Nutrition


Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!